UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Davidson, Cullen L.
Sawyer, Wallace G.
Sumerlin, Brent S.
Uruena Vargas, Juan M.
Abrégé
The present disclosure provides for compositions including at least one type of watersoluble polymer, methods of making the water-soluble polymer, structures having the watersoluble polymer disposed thereof, and methods of use thereof. The water-soluble polymer of the present disclosure can be used for gelation and restoration of the functional biological properties of mucinated networks and surfaces.
C08L 33/24 - Homopolymères ou copolymères des amides ou des imides
C08F 20/18 - Esters des alcools ou des phénols monohydriques des phénols ou des alcools contenant plusieurs atomes de carbone avec l'acide acrylique ou l'acide méthacrylique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
ENTRINSIC, LLC (USA)
Inventeur(s)
Vidyasagar, Sadasivan
Grosche, Astrid
Xu, Xiaodong
Lin, Shanshan
Cheuvront, Samuel
Kenefick, Robert
Gatto, Stephen
Abrégé
Formulations comprising particular free amino acids useful for promoting hydration and/or intestinal barrier function in a subject in need thereof are described herein. Such formulations and methods using same are useful for promoting hydration and/or intestinal barrier function in a subject in need thereof. Such subjects may be healthy, but in need of a formulation that promotes rapid hydration (e.g., within 15-90 minutes post-administration) or promotes intestinal barrier function; or such subjects may be afflicted by a disorder or disease associated with dehydration or impaired intestinal barrier function, respectively. Use of amino acid formulations described herein for promoting hydration and/or intestinal barrier function in a subject in need thereof, for the treatment of disorders or diseases associated dehydration and/or impaired intestinal barrier function, and in the preparation of a medicament for the treatment of disorders or diseases associated with dehydration and/or impaired intestinal barrier function are encompassed herein.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Baharloo, Raheleh
Tighe, Patrick J.
Rashidi, Parisa
Principe, Jose C.
Andalib, Arash
Abrégé
Various embodiments of the present disclosure provide systems and methods for prediction of a risk for mild or severe persistent post-operative pain (POP) for an individual of interest. A risk prediction may be determined based at least in part on a cohort predictive model. The cohort predictive model is associated with a surgical type cohort and initialized with historical multivariate intra-operative vital sign data associated with binary classifications of mild or severe persistent post-operative pain. Using complex higher-order singular value decomposition, phase information for the historical multivariate intra-operative vital sign data is determined. A relationship between phase information and mild or severe persistent POP is then determined using discriminant analysis. Subsequently, phase information for multivariate intra¬ operative vital sign data for an individual of interest is provided to a cohort predictive model, which uses the determined relationship to classify the individual of interest. The risk prediction then comprises the classification.
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
4.
AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSTROPHIES
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
VOVA IDA THERAPEUTICS INC (USA)
Inventeur(s)
Bannister, Thomas D.
Lasmezas, Corinne
Zhou, Minghai
Rahaim, Ronald J. Jr.
Abrégé
Provided are, inter alia, compounds having a structure of Formula (X), (XI), (XII), or (XIII), or a subordinate structure thereof, composition including the same and methods of use.
A61K 31/502 - Pyridazines; Pyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. cinnoline, phtalazine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
6.
COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
VOVA IDA THERAPEUTICS, INC. (USA)
Inventeur(s)
Bannister, Thomas D.
Lasmezas, Corinne
Zhou, Minghai
Ullah, Sultan
Abrégé
Provided are, inter alia, compounds having a structure of Formulae (X) to (XVII), or a subordinate structure thereof, composition including the same and methods of use.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
7.
METHODS AND COMPOSITIONS FOR TREATMENT OF FRIEDREICH'S ATAXIA
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
AAVANTIBIO, INC. (USA)
Inventeur(s)
Corti, Manuela
Byrne, Barry John
Zolotukhin, Irene
Abrégé
Provided for herein are polynucleotides, including codon-optimized polynucleotides, encoding genes for use in, for example, virally-mediated gene therapy for Friedreich's ataxia. Some embodiments related to viral vector constructs for use in such gene therapy. Also provided are dosing regimens and therapeutic combinations or systems for use in modulating immune responses to such viral vectors.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Sweeney, Hugh Lee
Abrégé
The present disclosure is related to compositions and methods useful in treating heart conditions. The disclosed compositions and methods are based on gene therapies comprising a recombinant AAV vector for delivering two or more transgenes into the heart of a subject, wherein the transgenes encode an S100A1 protein and a cardiac Apoptosis Repressor with caspase recruitment Domain (cARC) apoptotic inhibitor, respectively. In various embodiments, the compositions and methods disclosed herein comprise vectors comprising S100A1 and/or cARC cDNA sequences that are codon-optimized for expression in humans. In various embodiments, the compositions and methods disclosed herein comprise vectors with improved packaging efficiencies. In some aspects, targeting multiple sources of one or more heart conditions can provide synergistic benefits during treatment.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
9.
DIPHENHYDRAMINE AND LACTOFERRIN FOR PREVENTION AND TREATMENT OF COVID-19
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ostrov, David A.
Norris, Michael
Abrégé
Compositions and formulations comprising diphenhydramine and lactoferrin for preventing or treating infection by a SARS-CoV-related betacoronavirus are described. Methods of using the compositions and formulations are also described. The methods include administering to a patient at risk of being infected by a SARS-CoV-related betacoronavirus or suffering from SARS-CoV-related betacoronavirus-related illness a composition or formulation comprising diphenhydramine and lactoferrin.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Lasmezas, Corinne
Zhou, Minghai
Abrégé
Methods of preventing disease or treating a subject likely to develop or having a neurodegenerative, degenerative or metabolic disease include administration of nicotinamide dinucleotide (NAD) modulating agents. Compositions include one or more agents which increase or decrease NAD in vivo or in vitro.
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p.ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Dai, Mingji
Cui, Chengsen
Cai, Zhongjian
Adibekian, Alexander
Dwyer, Brendan
Abrégé
The present disclosure provides the first asymmetric total synthesis and target identification of the curcusone natural products. The novel convergent synthesis is built upon a cheap and abundant chiral pool molecule (8) and features a thermal [3,3]-sigmatropic rearrangement and an FeCl3-promoted global hydrolysis/adol condensation cascade to rapidly construct the critical cycloheptadienone core. By performing chemoproteomics with the alkyne probe 37, we identified the previously "undruggable" oncogenic protein BRAT1 as a key cellular target of 1d. Furthermore, 1d inhibits BRAT1 in cancer cells, thereby reducing cancer cell migration, increasing susceptibility to DNA damage, and inducing chemosensitization to the approved drug etoposide. Compound 1d is the first known small-molecule inhibitor for BRAT1, a master regulator of the DDR and DNA repair. Composition matters and methods of uses are within the scope of this disclosure.
C07C 229/12 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons à des atomes de carbone de squelettes carbonés acycliques
C07C 45/68 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par des réactions ne créant pas de groupe C=O par modification de la taille du squelette carboné par augmentation du nombre d'atomes de carbone
C07C 49/743 - Composés non saturés comportant un groupe cétone faisant partie d'un cycle contenant des groupes hydroxyle avec insaturation autre que celle des cycles, p.ex. humulones, lupulones
C07D 295/145 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de car avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile avec les atomes d'azote du cycle et les atomes de carbone comportant trois liaisons à des hétéro-atomes liés à la même chaîne carbonée, qui n'est pas interrompue par des carbocycles
12.
CANNABIS PLANT DERIVED EXTRACELLULAR VESICLES AND THERAPEUTIC METHODS USING THE SAME
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Azari, Hassan
Schmittgen, Thomas D.
Nassiri Koopaei, Nasser
Reynolds, Brent
Abrégé
Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety. New data using hemp derived EVs to treat cancers in the brain and to impact precursor cells in the brain and isolation of EVs are included. In addition, disclosed is an improvement on the efficacy of intra-nasal delivery and oral delivery when using EVs.
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Hromas, Robert
Abrégé
Disclosed herein are anti-CCL21 antibodies useful in treating autoimmune diseases, treating or preventing allograft transplant rejection, and treating metastatic cancer or preventing cancer metastasis in a subject.
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Boye, Shannon E.
Boye, Sanford L.
Abrégé
The present disclosure provides for improved recombinant AAV therapies for the treatment of X-linked retinoschisis (XLRS). These therapies are designed for administration to subjects, such as human subjects, including humans diagnosed with or suffering from XLRS.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Angelini, Thomas E.
Dobson, Jon P.
Duraivel, Senthilkumar
Sumerlin, Brent S.
Abrégé
In one aspect, the disclosure relates to a support material for 3D printing of soft materials having feature sizes <5 µm that persist over time, methods of 3D printing using the same, and articles that include soft matter constructed using the disclosed methods. In one aspect, the support materials can be jammed inverse emulsions having silicone oils as the continuous phase and glycerol/water mixtures as the dispersed phase. In some aspects, the support materials also include a surfactant. In any of these aspects, the support materials can be optically clear.
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
B33Y 30/00 - Appareils pour la fabrication additive; Leurs parties constitutives ou accessoires à cet effet
B33Y 80/00 - Produits obtenus par fabrication additive
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
ENTRINSIC, LLC (USA)
Inventeur(s)
Vidyasagar, Sadasivan
Grosche, Astrid
Xu, Xiaodong
Lin, Shanshan
Gatto, Stephen
Kenefick, Robert
Cheuvront, Samuel
Abrégé
Amino acid formulations useful for treating diarrhea in a subject in need thereof are described herein. Such amino acid formulations and methods comprising administering same to a subject are useful for treating diarrhea, particularly diarrhea caused by or associated with bacterial infections wherein secretagogue-stimulated anion secretion from the intestinal crypt contributes to at least one symptom of diarrhea in the subject. Use of these amino acid formulations for the treatment of diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypt are encompassed herein, as are their use in the preparation of a medicament for the treatment of diarrhea in general or diarrhea associated with secretagogue- stimulated anion secretion from the intestinal crypt.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
ENTRINSIC, LLC (USA)
Inventeur(s)
Vidyasagar, Sadasivan
Grosche, Astrid
Xu, Xiaodong
Angoli, Damiano
Gatto, Stephen J.
Abrégé
Formulations comprising combinations of free amino acids useful for treating ARDS, asthma, orallergic rhinitis are described herein. Use of such amino acid formulations for treating ARDS, asthma, or allergic rhinitis in a subject in need thereof; in methods for treating ARDS, asthma, or allergic rhinitis in a subject in need thereof; and/or in the preparation of a medicament for the treatment of ARDS, asthma, or allergic rhinitis are encompassed herein.
The present disclosure provides for metal nanoparticles, such as gold nanoparticles that have six pointed areas so that the metal nanoparticle resembles a six-pointed star. The distance from opposing points of the six-pointed star is about 400 to 480 nanometers. The present disclosure also provides for a method of making the nanoparticle, where in an aspect, the method is a light-driven synthesis.
B22F 9/24 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques liquides, p.ex. de solutions
19.
MULTILAMELLAR RNA NANOPARTICLE VACCINE AGAINST SARS-COV-2
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Sayour, Elias
Mendez-Gomez, Hector Ruben
Castillo Caro, Paul Antonio
Jones, Noah Thomas
Mitchell, Duane A.
Abrégé
The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2 protein. Methods of making such nanoparticles are further provided herein. Additionally, related cells, populations of cells, pharmaceutical compositions comprising the presently disclosed nanoparticles are provided. Methods of increasing an immune response against a tumor in a subject, methods of delivering RNA molecules to an intra-tumoral microenvironment, lymph node, and/or a reticuloendothelial organ in a subject, and methods of treating a subject with a disease are furthermore provided.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Disney, Matthew D.
Abrégé
Embodiments of methods are disclosed for inhibiting, regulating and/or otherwise affecting or managing the pri-miR- 17-92 cluster, and certain pre-miRNA's embedded in the cluster as well as the pre-miRNA's themselves as isolated forms, as members of a library, present in oncogenic and/or polycystic cell lines and/or that are present in breast cancer, prostate cancer and/or polycystic kidney disease in animals or humans, or present in any other disease in which the pri-miR-17-92 cluster and the certain pre-miRNAs within in it cause or contribute to disease. The methods utilize compounds that target the structural feature or features of the pri-miR-17-92 cluster and/or the certain pre-miRNA's. The pre- miRNA's are members of the pre-miRNA-X group which includes one or more of pre-miR- 17, pre- miR-18a, pre-miR-19a, pre-miR-19b-1, pre-miR-20a, and pre-miR-92a-1 or any combination thereof. The compounds incorporate a dimeric formula of a binding moiety for the certain pre-miRNA-X's. The binding moiety can bind or complex with structural feature(s) of the certain pre-miRNA-X's without specificity for the particular nucleotide sequence of the structural features. The binding moiety nevertheless is selective for the certain structural feature(s) so that it does not bind with other pre-miRNA's not having the certain structural feature(s).
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Boye, Shannon E.
Boye, Sanford L.
Sweeney, H. Lee
Calabro, Kaitlyn
Abrégé
Disclosed are compositions and methods for treating diseases of the mammalian eye, and in particular, complications of the retina associated with Usher syndrome IB (USH1B). Further disclosed are compositions and methods for treating diseases of the mammalian inner ear, and in particular, complications of ear hair cells associated with Usher syndrome IB (USH1B). The disclosure provides improved AAV -based, dual vector systems that facilitate the expression of full-length proteins whose coding sequences exceed that of the polynucleotide packaging capacity of an individual AAV vector. Described herein are modified hybrid dual vector systems that shift the coding sequence for the MY07A tail domain from the front-half vector to the back-half vector by altering the split point (e.g., from between exons 23 and 24, to between exons 21 and 22), in order to eliminate the production of truncated MY07A protein. Further described herein are improved, codon-modified hybrid and overlap vector systems in which putative stop codons and residual sequences in non-coding sequences are removed.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Mitchell, Duane
Flores, Catherine
Francis, Connor
Abrégé
The disclosure provides methods of treating coronavirus infections (e.g., COVID-19) by administering hematopoietic stem cells, with or without an immune checkpoint inhibitor (e.g., PD-1 antagonist). The disclosure also provides methods of treating coronavirus infections (e.g., COVID-19) by adoptive cell transfer of polyclonal T cells and coronavirus- specific T cells (e.g., SARS-CoV-2-specific T cells).
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Sayour, Elias
Mendez-Gomez, Hector Ruben
Abrégé
The present disclosure provides methods of increasing sensitivity of a tumor to treatment with an immune checkpoint inhibitor (ICI) in a subject and methods of treating a subject with an immune checkpoint inhibitor (ICI)-resistant tumor. The methods comprise administering to the subject a composition comprising a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer. Also provided are methods of increasing the number of activated plasmacytoid dendritic cells (pDCs) in a subject in need thereof, comprising administering to the subject a composition comprising a nanoparticle comprising a positivelycharged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer.
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation utilisant la micro-encapsulation, p.ex. utilisant des vésicules liposomiques
24.
RNA-LOADED NANOPARTICLES AND USE THEREOF FOR THE TREATMENT OF CANCER
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Sayour, Elias
Mendez-Gomez, Hector Ruben
Qdaisat, Sadeem
Deleyrolle, Loic Pierre
Mitchell, Duane
Abrégé
Provided herein are compositions comprising a liposome comprising ribonucleic acid (RNA) molecules and a cationic lipid, wherein the RNA molecules bind to or encode an epitope of a nucleic acid encoding a fusion protein expressed by a tumor. The disclosure also provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, and nucleic acid molecules in the nucleic acid layers comprise a sequence of a nucleic acid molecule expressed by slow-cycling cells (SCCs). Also provided herein are methods of making a nanoparticle and methods of increasing an immune response against a tumor in a subject. Methods of treating a subject with a disease are provided herein.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Zheng, Guangrong
Zhou, Daohong
Zhang, Xuan
Hu, Wanyi
Liu, Xingui
Lyu, Dongwen
Yuan, Yaxia
Thummuri, Dinesh
Abrégé
The invention is directed towards compounds (e.g., Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof), their mechanism of action, and methods of modulating proliferation activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof).
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Ding, Yousong
Jiang, Guangde
Abrégé
The present disclosure relates to compositions comprising nitroreductase enzymes; plants, plant calluses, plant seeds, and vegetables incorporating genes expressing nitroreductase enzymes; methods for stably and operably incorporating genes expressing nitroreductase enzymes into plants and plant tissues; wherein the nitroreductase enzymes are capable of reducing nitro groups on phytotoxic and/or otherwise harmful compounds such as, for example, thaxtomins, wherein the thaxtomins are secreted by plant pathogenic bacteria and/or exogenously applied as an agricultural composition such as an herbicide, and wherein reducing the nitro groups renders the thaxtomins non-damaging or reduces the level of damage from the thaxtomins to the plants expressing the nitroreductase enzymes.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Disney, Matthew D.
Childs-Disney, Jessica L.
Abrégé
Small molecule compounds and corresponding dimers having inhibitory activity against pre-miR-21 RNA and related methods for treatment of neoplastic disease such as cancer and especially cancers expressing miR-21 are disclosed.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Rader, Christoph
Hwang, Dobeen
Abrégé
The present invention provides modified catalytic antibody 38C2 with arylation of the reactive lysine residue (Lys99). The Lys99 residue is arylated with a heteroaryl methyl sulfonyl compound such as methylsulfone phenyl oxadi azole (MS- PODA). The invention also provides antibody conjugated agents (e.g., antibody drug conjugates) that contain an agent moiety that is site-specifically conjugated to 38C2 via a methyl sulfonyl compound. Further provided in the invention are methods of making the antibody conjugated agents and therapeutic applications of the antibody conjugated agents.
A61K 47/51 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Spiess, Bruce Davis
Tan, Weihong
Abrégé
Compounds and compositions for determining the level of antithrombin (ATIII) in a sample are described. Methods of forming the compounds and compositions are also described. Methods of using the compounds and compositions to quantify the level of ATIII in a subject are further described. The methods can be used to facilitate determining a dosage or heparin or ATIII to administer to a patient.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Coronel, Monica Banez
Abrégé
Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting certain repeat-associated non-ATG (RAN) proteins in a subject (e.g., a subject having or suspected of having a disease associated with a CAG and/or CTG repeat expansion). In some embodiments, methods described by the disclosure comprise detecting one or more RAN proteins in a biological sample obtained from a subject by an immunoassay using one or more antibodies that target homopolymeric repeat regions of RAN proteins. In some embodiments, the disclosure relates to kits comprising one or more antibodies that target homopolymeric repeat regions of RAN proteins, and an immunoassay plate and/or reagents. In some embodiments, the disclosure provides methods of producing anti-RAN protein antibodies.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Laboissonniere, Lauren A.
Abrégé
Aspects of the disclosure relate to compositions and methods for eliciting (or enhancing) anti-repeat-associated non-ATG (RAN) protein antibody expression or production in a subject. Administration of the compositions according to the methods of the present disclosure may in some embodiments result in decreased levels of RAN protein expression and/or aggregation. Such compositions and methods may therefore be useful for the treatment of diseases and disorders known to be associated with RAN proteins.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
32.
DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Laboissonniere, Lauren A.
Nguyen, Lien
Abrégé
Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting anti-repeat-associated non-ATG (RAN) protein antibodies in a subject (e.g., a subject that has been administered a therapeutic anti-RAN protein antibody or a vaccine against a disease or disorder associated with RAN protein expression, translation, and/or accumulation, for example amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD)). In some embodiments, methods described by the disclosure comprise detecting one or more anti-RAN protein antibodies in a biological sample obtained from a subject by an electrochemiluminescence-based immunoassay using one or more target di-amino acid repeat peptides. In some embodiments, the disclosure relates to kits comprising one or more di-amino acid repeat peptides and an electrochemiluminescence-based immunoassay plate and/or reagents.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
33.
AAV CAPSID VARIANTS FOR TARGETING HUMAN GLIOBLASTOMA CELLS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Zolotukhin, Sergei
Tran, David
Kondratov, Oleksandr
Abrégé
Described herein are AAV particles having capsid proteins with amino acid substitutions that confer increased affinity for and transduction of glioma cells. The disclosed capsid proteins may be used in conjunction with any therapeutic transgene for treatment of cancer, including in the manufacture of an AAV particle. Also described are methods of identifying AAV variants having increased affinity for and transduction of specific tumor cell types.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Sweeney, Hugh Lee
Abrégé
Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues. Provided here are variant AAV capsid proteins and variant capsid protein containing particles. Compositions of these variant AAV particles can be used to alter tissue tropism and transduction efficiency. In some embodiments, compositions described in this application are useful to produce rAAV particles, and/or to deliver one or more genes of interest to a target tissue.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Sweeney, Hugh Lee
Abrégé
The present disclosure is related to compositions and methods useful in treating heart conditions. The disclosed compositions and methods are based on gene therapies comprising a recombinant AAV vector for delivering two or more transgenes into the heart of a human subject, wherein the transgenes comprise an S100A1 protein and a cardiac Apoptosis Repressor with caspase recruitment Domain (cARC) apoptotic inhibitor. In various embodiments, the compositions and methods disclosed herein comprise vectors comprising S100A1 and/or cARC cDNA sequences that are codon-optimized for expression in humans. In some aspects, targeting multiple sources of one or more heart conditions can provide synergistic benefits during treatment.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Golde, Todd E.
Ran, Yong
Goodwin, Marshall
Cruz, Pedro
Levites, Yona
Abrégé
Provided herein are compositions and methods for the stable production of bioactive small peptides of interest through delivery to target cells based on the fusion of small peptides of interest to a collagen domain of a C1qTNF protein to produce a novel scaffold protein capable of multimerization. Advantageously, the fusion proteins, compositions and methods of the present disclosure meet existing needs in the art by providing for higher stable expression and longer stability of intracellular and secretable peptides of interest. Additionally, the fusion proteins, compositions and methods of the present disclosure provide for improved binding affinity of expressed receptor peptides with ligand binding partners in the target cell. Further provided herein are polynucleotide constructs encoding the described fusion proteins and recombinant adeno-associated viral particles comprising these polynucleotides. Also provided herein are pharmaceutical compositions and nanoparticles that comprise the described fusion proteins. Further provided herein are methods of treating a subject by administering the described fusion proteins, rAAV particles, compositions and/or nanoparticles.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Sayour, Elias
Mendez-Gomez, Hector Ruben
Mitchell, Duane
Rinaldi, Carlos
Abrégé
The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer. Methods of making such nanoparticles are further provided herein. Additionally, related cells, populations of cells, pharmaceutical compositions comprising the presently disclosed nanoparticles are provided. Methods of increasing an immune response against a tumor in a subject, methods of delivering RNA molecules to an intra-tumoral microenvironment, lymph node, and/or a reticuloendothelial organ in a subject, and methods of treating a subject with a disease are furthermore provided.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Nguyen, Lien
Abrégé
Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as Alzheimer's disease (AD). In some embodiments, the disclosure relates to identifying a subject having a RAN protein- associated disease by detecting expression or activity of repeat-associated non-ATG (RAN) translation proteins (e.g., RAN proteins). In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof an agent that reduces expression or activity of RAN proteins.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
39.
G-PROTEIN BIASED OPIOID RECEPTOR AGONIST/ANALGESICS WITH REDUCED ARRESTIN RECRUITMENT
UNIVERSITY OF HEALTH SCIENCES & PHARMACY IN ST. LOUIS (USA)
UNIVERSITY OF SOUTHERN CALIFORNIA (USA)
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
MEMORIAL SLOAN KETTERING CANCER CENTER (USA)
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Majumdar, Susruta
Katritch, Vsevolod
Roth, Bryan
Mclaughlin, Jay
Zaidi, Saheem
Uprety, Rajendra
Pasternak, Gavril, W. (deceased)
Abrégé
In some aspects, the present disclosure provides compounds of the formula: (I) (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Kel'In, Alexander V.
Nanna, Alex R.
Rader, Christoph
Theile, Christopher
Pierson, Justin
Fitzgerald, Kevin
Voo, Zhi Xiang
Abrégé
The disclosure is directed to dual variable domain immunoglobulin double-stranded RNA conjugates that are advantageous for inhibition of target gene expression, as well as compositions suitable for therapeutic use. The dual variable domain immunoglobulin comprises a first variable domain that binds to a binding target, and a second variable domain that comprises a reactive residue, where the linker is covalently conjugated to the reactive residue. The dsRNA is linked to the linker and is capable of inhibiting the expression of the target gene by RNA interference. The disclosure also provides pharmaceutical compositions comprising these conjugate and methods of inhibiting the expression of a target gene by administering these conjugates, e.g., for the treatment of various disease conditions.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Griffin, Patrick R.
Chang, Mi Ra
Fisherman, Jason
Suzman, Peter
Abrégé
Disclosed herein are methods and uses of the polypharmacological modulator SR1903 and related compounds for inhibiting triggering receptor expressed on myeloid cells-1 (TREM-1) and treating diseases and conditions that are related to or mediated by TREM-1, such as inflammatory diseases, autoimmune diseases, metabolic disorders, and castration resistant prostate cancer (CRPC).
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. 1,2-oxazines
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Zhou, Daohong
Pal, Pratik
Liu, Xingui
Thummuri, Dinesh
Hu, Wanyi
Zhang, Peiyi
Lyu, Dongwen
Yuan, Yaxia
Zhang, Xuan
Zheng, Guangrong
Abrégé
The specification is directed to a compound of formula (I) , or a 5 pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof:Y-L2-R-L1-Y2 Formula (I);wherein Y, L2, R, L1 and Y2 are as disclosed herein. Also disclosed is a method of their synthesis, their mechanism of action, methods of modulating proliferation activity, use and methods of treating diseases and disorders using the compounds described herein. The compounds as dislosed herein can be used for degrading a B-cell lymphoma 2 (Bcl-2) protein, or treating a Bcl-2-mediated cancer.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Tran, David
Le, Son Bang
Abrégé
Provided methods of inhibiting a glioblastoma stem-like cell (GSC), methods of treating a subject with glioblastoma, and methods of reprogramming an astrocyte to a glioblastoma stem-like cell (GSC).
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Boye, Shannon E.
Boye, Sanford L.
Abrégé
The disclosure provides rAAV particles comprising a new capsid variant, AAV44.9(E531D). The disclosure also provides rAAV particles comprising AAV44.9(E531D) for treatment of the eye, including treatment of retinal disorders. In particular embodiments, the disclosure provides rAAV particles comprising an AAV44.9(E531D) capsid that exhibits enhanced lateral spread after subretinal injection to a fovea of the subject, wherein detachment of the fovea is minimized. The disclosure further provides rAAV particles comprising an AAV44.9(E531D) capsid and a polynucleotide encoding a heterologous nucleic acid sequence. Methods of treatment comprising administering rAAV particles to a mammal in need thereof, and methods of transducing photoreceptor and RPE cells with rAAV particles, are also provided.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
46.
AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Vidyasagar, Sadasivan
Grosche, Astrid
Xu, Xiaodong
Lin, Shanshan
Prabhakaran, Sreekala
Abrégé
Provided herein are amino acid compositions useful for increasing the translocation of the cystic fibrosis transmembrane conductance (CFTR) protein from the cytoplasm to the plasma membrane, particularly in epithelial cells. Methods for increasing the concentration of CFTR in the plasma membrane, increasing chloride ion transport, and increasing water transport are also provided. These compositions and methods are useful in treating cystic fibrosis in subjects bearing one or more mutations in the CFTR protein. Use of these compositions for the treatment of cystic fibrosis and in the preparation of a medicament for the treatment of cystic fibrosis are also encompassed herein.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Martemyanov, Kirill
Grill, Brock
Abrégé
The present invention provides methods for modulating opioid receptor mediated analgesic effect, e.g., promoting or enhancing analgesia in subjects in need of pain relief. Also provided in the invention are methods for ameliorating or suppressing withdrawal symptoms in subjects with chronic opioid use. These methods of the invention entail administering to the subjects in need of treatment a therapeutically effective amount of a GPR139 antagonist compound. The invention further provides methods for identifying novel compounds that can be useful for modulating opioid receptor mediated analgesic effect.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p.ex. azétidine
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/175 - Amides, p.ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p.ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p.ex. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Leurs thio-analogues
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Miller, Courtney
Griffin, Patrick
Kamenecka, Theodore
Rumbaugh, Gavin
Surman, Matthew
Young, Steve
Duddy, Steven
Radnai, Laszlo
Abrégé
The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis/marijuana, nicotine, and activities including gambling Compounds are of general formula (I) with substituents as defined herein.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinoxaline, phénazine
A61K 31/502 - Pyridazines; Pyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. cinnoline, phtalazine
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
A61K 31/538 - 1,4-Oxazines, p.ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p.ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. loxapine, staurosporine
A61P 25/18 - Antipsychotiques, c. à. d. neuroleptiques; Médicaments pour le traitement de la manie ou de la schizophrénie
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
50.
MATERIALS AND METHODS FOR TREATING STRESS-RELATED DISORDERS AND CANCER
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Golde, Todd Eliot
Futch, Hunter S.
Moore, Brenda Dawn
Giasson, Benoit
Abrégé
Disclosed herein are materials and methods for the treatment of stress-related disorders and cancer. The disclosure provides an antibody, or antigen binding fragment thereof, that specifically binds to a region of corticotropin-releasing hormone (CRH). The disclosure also provides methods of treating a disorder associated with HPA axis activation, such as a stress-related disorder or cancer, comprising administering to a subject in need thereof an antibody or antigen binding fragment thereof described herein in an amount effective to treat the disorder.
C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une oxydoréductase
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Sweeney, Hugh Lee
Sleeper, Margaret Mary
Abrégé
The present invention is related to compositions and methods useful in treating heart conditions. The disclosed compositions and methods are based on an AAV therapy comprising a recombinant AAV vector for delivering two or more transgenes into the heart of a subject, wherein the transgenes comprise an S100 family protein and an apoptotic inhibitor. In some aspects, targeting multiple sources of one or more heart conditions can provide synergistic benefits during treatment.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
C12N 15/12 - Gènes codant pour des protéines animales
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventeur(s)
Lewin, Alfred S.
Hauswirth, William W.
Massengill, Michael T.
Beltran, William
Aguirre, Gustavo D.
Cideciyan, Artur
Jacobson, Samuel
Abrégé
Aspects of the disclosure relate to methods and compositions useful for treating retinitis pigmentosa. In some aspects, the disclosure provides compositions and methods for delivering an interfering RNA to a subject in order to reduce expression of one or both alleles of an endogenous RHO gene (for example a mutant rho allele associated with retinitis pigmentosa) in a subject. In some embodiments, a replacement RHO coding sequence that is resistant to the interfering RNA also is delivered to the subject.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Grippin, Adam J.
Mitchell, Duane
Dobson, Jon P.
Sayour, Elias
Monsalve, Adam
Abrégé
Provided herein is a liposome comprising ribonucleic acid (RNA) molecules, a lipid mixture comprising DOTAP and cholesterol, and iron oxide nanoparticles (IONPs). Also provided herein is a liposome comprising ribonucleic acid (RNA) molecules and a lipid mixture comprising DOTAP and cholesterol, wherein the DOTAP and cholesterol are present in the lipid mixture at a DOTAP:cholesterol ratio of about 3:1 by mass. Related cells comprising the liposome, populations of cells, and compositions are also provided. Methods of making a liposome and methods of using the liposome are further provided.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Golub, Howard L.
Chauhan, Anuj
Williams, Michael
Abrégé
The present disclosure relates to nozzles for removing a preservative from a fluid comprising a therapeutic agent to an eye. More particularly, the nozzles disclosed herein may minimize patient exposure to preservative by rapidly and selectively removing a preservative from a solution comprising a therapeutic agent. An example nozzle may comprise a flow diverter which directs a flow path from a fluid inlet to a fluid outlet over a length longer than the distance from the inlet to the outlet. In some cases, the nozzle may comprise a preservative removing agent.
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeux; Dispositifs pour mettre en place des verres de contact; Dispositifs pour corriger le strabisme; Appareils pour guider les aveugles; Dispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
A61M 35/00 - Dispositifs pour appliquer des agents, p.ex. des remèdes, sur le corps humain
B05B 1/14 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage avec des filtres placés dans ou à l'extérieur de l'orifice de sortie
B05B 1/34 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage agencés pour influencer la forme de l'écoulement du liquide ou d'autre matériau fluide, p.ex. pour produire une turbulence
B65D 25/42 - Tuyères ou goulottes formant corps ou fixées à demeure
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques - Détails; Accessoires à cet effet
55.
LIVER TROPIC RECOMBINANT AAV6 VECTORS THAT EVADE NEUTRALIZATION
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Samulski, R. Jude
Agbandje-Mckenna, Mavis
Bennett, Antonette
Abrégé
As demonstrated herein, a modified recombinant AAV6 vector is provided that transduces the liver and has reduced neutralization of transduction of liver by ADK6 antibody. Accordingly, embodiments of the invention relate to liver tropic rAAV6 vectors that evade neutralization.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
The present technology provides compounds of Formula I (or pharmaceutically acceptable salts and/or solvates thereof) that are useful in treating a CNS-related disorder such as schizophrenia, schizoaffective disorder, migraine, depression, pain, drug addiction, drug use, and/or drug seeking behavior. Also provided are compositions, medicaments, and methods including such compounds.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Agbandje-Mckenna, Mavis
Mietzsch, Mario
Mckenna, Robert
Abrégé
Provided herein are compositions and methods for packaging a recombinant adeno- associated virus (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Asokan, Aravind
Havlik, Patrick
Agbandje-Mckenna, Mavis
Smith, James Kennon
Mietzsch, Mario
Abrégé
The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo. This disclosure also relates to recombinant adeno associated virus (rAAV) capsid proteins comprising one or more amino acid substitutions in the 5-fold region of the rAAV capsid that result in decreased reactivity to neutralizing antibodies, and their use as gene delivery vehicles.
Disclosed herein are peptide analogs of human FGF. These peptide analogs exhibit improved therapeutic activity and fewer side effects when used in humans. Also disclosed are pharmaceutical or cosmetic compositions comprising the FGF analogs and pharmaceutically or cosmetically acceptable carriers or excipients. Also provided are methods of treating or preventing a disease in a subject that involves administering to the subject the disclosed FGF analogs.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
ENTRINSIC INC. (USA)
Inventeur(s)
Vidyasagar, Sadasivan
Gupta, Reshu
Gatto, Stephen
Abrégé
The subject invention provides compositions and methods for inhibiting the growth and/or proliferation of cancer cells. The subject invention also provides methods for treating cancer in a subject in need of such treatment by administering a composition described herein. The subject invention can be used to inhibit cancer cell growth by exposing the cells to a composition. The subject invention further provides cancer treatments that may be used in combination with surgery, chemotherapy, and/or radiation therapy.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Zu, Tao
Abrégé
The present disclosure provides the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in treating a neurological disease associated with repeat expansions and/or RAN protein accumulation, reducing the level of one or more repeat associated non-ATG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and/or biological sample. Also provided is the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in inhibiting RAN protein translation in a subject and in a biological sample (e.g., cells, tissue). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) for treating diseases associated with repeat expansions. Exemplary diseases associated with repeat expansions include, but are not limited to, C90RFf72 amyotrophic lateral sclerosis (ALS), or C90RFf72 frontotemporal dementia; myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia; Huntington' s disease; Fragile X Tremor Ataxia Syndrome (FXTAS); and Fragile XE syndrome (FRAXE).
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
62.
PRESERVATIVE REMOVAL FROM EYE DROPS CONTAINING HYDROPHILIC DRUGS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Chauhan, Anuj
Dixon, Phillip J.
Sekar, Poorvajan
Abrégé
A particulate plug for removing a preservative from a solution, suspension, or emulsion comprising a drug is presented. The plug comprises microparticles of a homopolymer comprising a hydrophilic repeating unit or of a copolymer comprising at least one hydrophilic repeating unit and at least one hydrophobic repeating unit. The microparticles are irregular- shaped rigid aggregates and are sized and packed to yield a hydraulic permeability greater than 0.01 Da. The homopolymers have absorbed portions of a preservative to be removed and/or a drug for delivery in solution, as can the copolymer.
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeux; Dispositifs pour mettre en place des verres de contact; Dispositifs pour corriger le strabisme; Appareils pour guider les aveugles; Dispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques - Détails; Accessoires à cet effet
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Nguyen, Lien
Abrégé
Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting repeat-associated non-ATG (RAN) proteins in a subject (e.g., a subject having or suspected of having a disease associated with RAN protein translation, for example amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD), or spinocerebellar ataxia type 36 (SCA36), or other diseases that produce poly(PR), poly(GR) or poly(GP) RAN proteins. In some embodiments, methods described by the disclosure comprise detecting one or more RAN proteins in a biological sample obtained from a subject by an electrochemiluminescence-based immunoassay using one or more anti-RAN protein antibodies. In some embodiments, the disclosure relates to kits comprising one or more anti-RAN antibodies and an electrochemiluminescence-based immunoassay plate and/or reagents.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/483 - Analyse physique de matériau biologique
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
64.
METHODS AND COMPOSITIONS FOR TREATING CONE-ROD RETINAL DYSTROPHY
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
EDITAS MEDICINE, INC. (USA)
Inventeur(s)
Boye, Shannon E.
Boye, Sanford L.
Maeder, Morgan
Abrégé
Provided herein are methods and compositions for treating an eye disorder, for example CORD6. Aspects of the disclosure relate to knocking out an autosomal dominant mutant GUCY2D gene.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Boye, Sanford L.
Dyka, Frank
Hauswirth, William W.
Akil, Omar
Abrégé
Provided herein are methods and compositions for expressing Otoferlin, e.g., utilizing adeno-associated viral (AAV) particles. Such methods and compositions may be useful for treatment of diseases such as Deafness, Autosomal Recessive 9 (DFNB9).
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Zu, Tao
Abrégé
Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure provides methods of inhibiting RAN protein translation by contacting a cell with an effective amount of an inhibitor of eIF2 phosphorylation or an inhibitor of protein kinase R (PKR). In some embodiments, methods described by the disclosure are useful for treating diseases associated with RAN protein translation, such as certain neurodegenerative diseases.
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligature; Utilisation de linkers non fonctionnels ou d'adaptateurs, p.ex. linkers contenant la séquence pour une endonucléase de restriction
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Zolotukhin, Sergei
Boye, Sanford L.
Boye, Shannon E.
Marsic, Damien
Gamlin, Paul D.
Abrégé
Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p.ex. des bactéries ou des cellules animales; Bibliothèques contenues ou présentées dans des vecteurs, p.ex. des plasmides; Bibliothèques contenant uniquement des micro-organismes ou des vecteurs
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Zolotukhin, Sergei
Boye, Sanford L.
Boye, Shannon E.
Marsic, Damien
Gamlin, Paul D.
Abrégé
ABSTRACT Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells. Date Recue/Date Received 2021-04-12
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Curtiss, Roy, Iii
Wang, Shifeng
Abrégé
Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissance; Stimulation de la croissance par élimination d'un composé chimique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ghivizzani, Steven C.
Abrégé
The present disclosure relates to compositions and methods for treatment of degenerative conditions of large weight-bearing joints, such as osteoarthritis, by intra-articular delivery of a codon-modified IL-1Ra encoding gene.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Chauhan, Anuj
Sekar, Poorvajan
Dixon, Phillip J.
Abrégé
A BAK removal device is constructed as a plug of microparticles of a hydrophilic polymeric gel that displays a hydraulic permeability greater than 0.01 Da. The polymer hydrophilic polymeric gel comprises poly(2-hydroxyethyl methacrylate) (pHEMA). The particles are 2 to 100 µm and the plug has a surface area of 30 mm2 to 2 mm2 and a length of 2 mm to 25 mm and wherein the microparticles of a hydrophilic polymeric gel has a pore radius of 3 to 60 µm.
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques - Détails; Accessoires à cet effet
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeux; Dispositifs pour mettre en place des verres de contact; Dispositifs pour corriger le strabisme; Appareils pour guider les aveugles; Dispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
B01D 39/16 - Autres substances filtrantes autoportantes en substance organique, p.ex. fibres synthétiques
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
ENTRINSIC BIOSCIENCE, INC. (USA)
Inventeur(s)
Vidyasagar, Sadasivan
Gupta, Reshu
Yin, Lianjie
Grosche, Astrid
Okunieff, Paul Gerson
Gatto, Stephen
Dennison, Daniel
Abrégé
The present disclosure provides compositions and methods for promoting stem cell and/or progenitor cell proliferation and/or differentiation. The provided compositions may be useful in treating a disease or condition that is related to mucosal barrier function, e.g., wound healing, treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or condition related to the aging of skin), treating a lung disorders (e.g., asthma), a condition related to improving mucosal barrier function, and/or treating injury to GI mucosa in a subject in need thereof. The present disclosure also provides methods for promoting the proliferation and/or differentiation of stem cells and/or the progenitor cells in a subject in need of such treatment by administering a composition. The ability to stimulate the proliferation and/or differentiation of stem cells and/or the progenitor cells in vivo, ex vivo and/or in vitro provides tremendous benefit. The present disclosure can be used to increase stem cell populations in in vivo, ex vivo and/or in vitro. Stem cell transplantation provides treatments and/or cures of many disease states, degeneration and/or injury.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
AMILYFE, LLC (USA)
Inventeur(s)
Vidyasagar, Sadasivan
Gupta, Reshu
Yin, Lianjie
Grosche, Astrid
Okunieff, Paul Gerson
Gatto, Stephen
Dennison, Daniel
Abrégé
The present disclosure provides compositions and methods for promoting stem cell and/or progenitor cell proliferation and/or differentiation. The provided compositions may be useful in treating a disease or condition that is related to mucosal barrier function, e.g., wound healing, treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or condition related to the aging of skin), treating a lung disorders (e.g., asthma), a condition related to improving mucosal barrier function, and/or treating injury to GI mucosa in a subject in need thereof. The present disclosure also provides methods for promoting the proliferation and/or differentiation of stem cells and/or the progenitor cells in a subject in need of such treatment by administering a composition. The ability to stimulate the proliferation and/or differentiation of stem cells and/or the progenitor cells in vivo, ex vivo and/or in vitro provides tremendous benefit. The present disclosure can be used to increase stem cell populations in in vivo, ex vivo and/or in vitro. Stem cell transplantation provides treatments and/or cures of many disease states, degeneration and/or injury.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Bartlett, Jeffrey S.
Ghivizzani, Steven, C
Abrégé
Methods and compositions for treating symptoms of conditions such as but not limited to osteoarthritis and rheumatoid arthritis. The methods may feature direct intraarticular injection of a recombinant self-complementary adeno-associated virus (sc-rAAV) with a vector adapted to express a modified IL-1Ra peptide. The methods of the present invention may express a therapeutically effective amount of the modified IL-1Ra peptide so as to ameliorating symptoms associated with the condition being treated.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Burke, Steven Keith
Bergeron, Raymond J., Jr.
Abrégé
The present disclosure provides safe and effective dosing regimens of metal chelators as treatment for metal overload disorders and, in particular, iron overload and associated conditions. In particular, the present disclosure provides use of a plurality of oral doses of (S)- 4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid (SP- 420) or a pharmaceutically acceptable salt, solvate or hydrate thereof for treating iron overload in a subject, wherein each dose is for administration every other day or less.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
LORAM TECHNOLOGIES, INC. (USA)
Inventeur(s)
Liesenfelt, Michael John
Baciak, James Edward
Grissom, Gregory Thomas
Abrégé
A method for image reconstruction includes irradiating an object with a beam of radiation from a radiation source, measuring an attenuated portion of the beam, estimating a density of the object, determining a predicted attenuated portion of the beam using the density estimate, and iteratively adjusting the density estimate of the object. The predicted attenuated portion and the measured attenuated portion are compared to determine a signal difference. The density estimate of each portion of the object is adjusted by scaling the density estimate using the average signal differences of rays that intersect the portion of the object. The density estimate may be repeatedly adjusted until a difference between consecutive density estimates is below a selected threshold or a predetermined number of adjustments have been completed. The attenuated portion of the beam may include a scattered portion and a transmitted portion.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Zolotukhin, Sergei
Kondratov, Oleksandr
Abrégé
Provided herein are methods and compositions useful in the production of recombinant AAV (rAAV) in insect cells. In some embodiments, methods and compositions include the use of modified Kozak sequences to express AAV VPl proteins in amounts that are useful for producing infective rAAV particles.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Grant, Maria A.
Salazar, Tatiana E.
Xie, Huisheng
Abrégé
Stimulation using EA of LI-4, LI- 11, GV-14 and GV-20 in humans, horses, and rodents results in mobilization of MSCs into systemic circulation. Methods are provided for increasing mesenchymal stem cells in the circulating blood of a mammal by contacting acupuncture points LI-4, LI- 11, GV-14, and GV-20 of the mammal with a therapeutically effective amount of EA stimulation to mobilize MSCs into the circulating blood of the mammal. Methods for treating damaged tissue, specifically damaged tendons are also provided. Isolated mesenchymal stem cells made according to these methods, methods of isolated them, and stem cell banks that store them are also provided.
A61H 39/00 - Dispositifs de physiothérapie pour localiser ou stimuler les endroits spécifiques de réflexe du corps, p.ex. acupuncture
A61N 1/20 - Application de courants électriques par électrodes de contact courants continus ininterrompus
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
80.
MANIPULATION OF EIF3 TO MODULATE REPEAT ASSOCIATED NON-ATG (RAN) TRANSLATION
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Ayhan, Fatma
Zu, Tao
Abrégé
Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure relates to methods for treating a subject having a disease associated with RAN protein translation by administering the subject a modulator of eIF3 or an eIF3 subunit, or an antibody that bind to a RAN protein.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
81.
AAV VECTORS FOR TREATMENT OF DOMINANT RETINITIS PIGMENTOSA
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventeur(s)
Lewin, Alfred S.
Hauswirth, William W.
Massengill, Michael T.
Beltran, William
Aguirre, Gustavo D.
Cideciyan, Artur
Jacobson, Samuel
Abrégé
Aspects of the disclosure relate to methods and compositions for treating retinitis pigmentosa. In some aspects, the disclosure provides compositions and methods for delivering an interfering nucleic acid (for example an interfering RNA) to a subject in order to reduce expression of one or both alleles of an endogenous rho gene (for example a mutant rho allele associated with retinitis pigmentosa) in the subject. In some embodiments, a replacement rho gene that is resistant to the interfering nucleic acid also is delivered to the subject.
C12N 15/79 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Rader, Christoph
Peng, Haiyong
Beerli, Roger
Waldmeier, Lorenz
Grawunder, Ulf
Abrégé
ROR1 Antibody Compositions and Related Methods The disclosure provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the disclosure are methods of using such antibodies in various diagnostic and therapeutic applications.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Asokan, Aravind
Agbandje-Mckenna, Mavis
Tse, Long Ping Victor
Gurda, Brittney
Abrégé
The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.
C07K 14/535 - CSF du type granulocyte; CSF du type granulocyte-macrophage
C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
85.
SYSTEM AND METHOD FOR INTERNAL INSPECTION OF RAIL COMPONENTS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
LORAM TECHNOLOGIES, INC. (USA)
Inventeur(s)
Belcher, Jeb E.
Grissom, Gregory Thomas
Baciak, James Edward
Jordan, Kelly Alexander
Nimmagadda, Jyothier
Cui, Shuang
Manuel, Michele Viola
Abrégé
An internal imaging system has a radiation source and a plurality of detectors positioned to receive portions of the plurality of collimated beams that have been attenuated by interaction with the target. The radiation source is configured to irradiate a target with a plurality of collimated beams of radiation. Two of the plurality of collimated beams of radiation may have different beam shapes. Another internal imaging system includes a radiation source configured to irradiate a target with at least one collimated beam of radiation and at least one detector. A planar rotating collimator is positioned adjacent to the radiation source and is configured to form the at least one collimated beam. The at least one detector is positioned to receive attenuated portions of the at least one collimated beam. The radiation source may be or include a neutron source. The detectors may be or include a plurality of neutron converters.
G01N 23/04 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux
B61K 9/10 - Installations de mesure pour surveiller la voie pour détecter les fissures dans les rails ou dans leurs soudures
G01N 23/05 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux en utilisant des neutrons
G01T 3/06 - Mesure de flux de neutrons avec des détecteurs à scintillation
86.
SYSTEM AND METHOD FOR INTERNAL INSPECTION OF RAIL COMPONENTS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
LORAM TECHNOLOGIES, INC. (USA)
Inventeur(s)
Belcher, Jeb E.
Grissom, Gregory Thomas
Baciak, James Edward
Jordan, Kelly Alexander
Nimmagadda, Jyothier
Cui, Shuang
Manuel, Michele Viola
Abrégé
An internal imaging system has a radiation source and a plurality of detectors positioned to receive portions of the plurality of collimated beams that have been attenuated by interaction with the target. The radiation source is configured to irradiate a target with a plurality of collimated beams of radiation. Two of the plurality of collimated beams of radiation may have different beam shapes. Another internal imaging system includes a radiation source configured to irradiate a target with at least one collimated beam of radiation and at least one detector. A planar rotating collimator is positioned adjacent to the radiation source and is configured to form the at least one collimated beam. The at least one detector is positioned to receive attenuated portions of the at least one collimated beam. The radiation source may be or include a neutron source. The detectors may be or include a plurality of neutron converters.
G01N 23/203 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la réflexion de la radiation par les matériaux en mesurant la rétrodiffusion
B61K 9/10 - Installations de mesure pour surveiller la voie pour détecter les fissures dans les rails ou dans leurs soudures
G01N 9/24 - Recherche du poids spécifique ou de la densité des matériaux; Analyse des matériaux en déterminant le poids spécifique ou la densité en observant la propagation de l'onde ou de la radiation des particules à travers le matériau
G01N 23/204 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la réflexion de la radiation par les matériaux en mesurant la rétrodiffusion en utilisant des neutrons
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (USA)
Inventeur(s)
Anchordoquy, Thomas J.
Gottlieb, Peter A.
Michels, Aaron
Ostrov, David
Abrégé
Methods of preventing, treating or ameliorating autoimmune diabetes by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of methyldopa. Pharmaceutical compositions containing therapeutically effective amounts of methyldopa in extended release formulations and methods of using the same are also provided.
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
88.
MESH SIZE CONTROL OF LUBRICATION IN GEMINI HYDROGELS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Sawyer, Wallace G.
Pitenis, Angela A.
Uruena, Juan Manuel
Nixon, Ryan M.
Schulze, Kyle D.
Angelini, Thomas E.
Abrégé
Provided herein is a soft contact lens. The lens comprises a lens body of a silicone hydrogel material and a coating of a non-silicone hydrogel thereon. The silicone hydrogel material comprises first repeating units of at least one hydrophilic vinylic monomer and second repeating units of (a) at least one silicone-containing vinylic monomer, (b) a silicone-containing vinylic macromer, or (c) a combination thereof. The coating has a thickness of at least 20 nm, wherein the soft contact lens has a targeted lubricity as measured by a surface mesh size of from 4.5 nm to 10.6 nm. Methods of making the contact lens is also provided.
C08L 51/08 - Compositions contenant des polymères greffés dans lesquels le composant greffé est obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone; Compositions contenant des dérivés de tels polymères greffés sur des composés macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
B29D 11/00 - Fabrication d'éléments optiques, p.ex. lentilles ou prismes
C08L 31/04 - Homopolymères ou copolymères de l'acétate de vinyle
C08L 33/00 - Compositions contenant des homopolymères ou des copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, chacun ne contenant qu'une seule liaison double carbone-carbone et un seul étant terminé par un seul radical carboxyl; Compositions contenant des dérivés de tels polymères
C08L 39/02 - Homopolymères ou copolymères de la vinylamine
C08L 39/06 - Homopolymères ou copolymères des N-vinylpyrrolidones
G02B 1/04 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques faits de substances organiques, p.ex. plastiques
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
UNM RAINFOREST INNOVATIONS (USA)
Inventeur(s)
Whitten, David G.
Pappas, Harry Craig
Hill, Eric H.
Schanze, Kirk S.
Parthasarathy, Anand
Huang, Yun
Corbitt, Thomas S.
Abrégé
Various embodiments disclosed relate to conjugated polyelectrolytes and methods of using the same. Various embodiments provide a conjugated polyelectrolyte including a subunit having the structure -R1-Y-R2-Z-. At each occurrence, R1 is independently chosen from 1,4-bonded phenylene substituted by -X-R3-R4 j times and 2,5-bonded thiophene substituted by -X-R3-R4 j times. At each occurrence, Y is independently chosen from a bond and -C=C-. At each occurrence, R2 is independently chosen from a bond, a substituted or unsubstituted phenylene, thiophenylene, azulenylene, heptalenylene, biphenylene, indacenylene, fluorenylene, phenanthrenylene, triphenylenylene, pyrenylene, naphthacenylene, chrysenylene, biphenylenylene, anthracenylene, and naphthylene. At each occurrence, Z is independently chosen from a bond and -C=C-. The variables j, R3, and R4 are as defined herein.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
GEORGIA TECH RESEARCH CORPORATION (USA)
Inventeur(s)
Marquez, Samantha M.
Fernandez-Nieves, Alberto
Angelini, Thomas, Ettor
Chang, Ya-Wen
Abrégé
A method or apparatus for three-dimensionally printing. The method may comprise causing a phase change in a region of the first material by applying focused energy to the region using a focused energy source, and displacing the first material with a second material. The apparatus may comprise a container configured to hold a first material, a focused energy source configured to cause a phase change in a region of the first material by applying focused energy to the region, and an injector configured to displace the first material with a second material. The first material may comprise a yield stress material, which is a material exhibiting Herschel-Bulkley behavior. The yield stress material may comprise a soft granular gel. The second material may comprise one or more cells.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Chauhan, Anuj
Hsu, Kuan-Hui
Abrégé
A BAK removal device is constructed as a plug of microparticles of a hydrophilic polymeric gel that displays a hydraulic permeability greater than 0.01 Da. The polymer hydrophilic polymeric gel comprises poly(2-hydroxyethyl methacrylate) (pHEMA). The particles are 2 to 100 µm and the plug has a surface area of 30 mm2 to 2 mm2 and a length of 2 mm to 25 mm and wherein the microparticles of a hydrophilic polymeric gel has a pore radius of 3 to 60 µm.
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
B65D 51/24 - Fermetures non prévues ailleurs combinées avec dispositifs auxiliaires pour des buts autres que la fermeture
92.
FUNCTIONAL ELECTRICAL STIMULATION CYCLING DEVICE FOR PEOPLE WITH IMPAIRED MOBILITY
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Dixon, Warren
Bellman, Matthew J.
Abrégé
Functional electrical stimulation (FES) cycling devices and associated methods are generally described. An FES cycling device may comprise a crank, two or more pedals connected to the crank, one or more sensors adapted to measure position and/or velocity of the crank, and one or more electrodes configured to deliver electrical stimulation to a person associated with the cycling device. In some cases, the FES cycling device further comprises a controller configured to receive input signals from the one or more sensors and deliver output signals to the one or more electrodes. In certain cases, the controller may dynamically generate a control signal to deliver an amount of electrical stimulation to a muscle group (e.g., quadriceps femoris, gluteal muscles, hamstring muscles) based on the value of a determined torque transfer ratio between a joint of the person and the crank of the cycling device. The electrical stimulation may, in some cases, cause the person to pedal the cycling device.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Hoffman, Brad, E.
Abrégé
Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed AAV-based gene therapeutic regimen for treating and/or ameliorating autoimmune disorders such as multiple sclerosis.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
C12N 15/12 - Gènes codant pour des protéines animales
94.
DELIVERY OF CARD PROTEIN AS THERAPY FOR OCULAR INFLAMMATION
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Ildefonso, Cristhian J.
Lewin, Alfred S.
Li, Qiuhong
Abrégé
The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating CARD to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Zhao, Bo
Guzman, Rafael
Abrégé
A catadioptric telescope is a modified version of a conventional Maksutov-Cassegrain optical telescope. In accordance with the invention, the reflecting surfaces of the primary mirror and the secondary spot mirror are on the second surfaces of the primary mirror and correcting lens, respectively. In further accordance with the invention, two of these telescopes can be joined together to form a binocular telescope array. The array can be easily customized to suit different remote sensing/satellite applications.
G02B 23/02 - Télescopes ou lunettes d'approche, p.ex. jumelles; Périscopes; Instruments pour voir à l'intérieur de corps creux; Viseurs; Pointage optique ou appareils de visée comprenant des prismes ou des miroirs
96.
IMPROVED RAAV VECTORS AND METHODS FOR TRANSDUCTION OF PHOTORECEPTORS AND RPE CELLS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Boye, Shannon E.
Boye, Sanford L.
Agbandje-Mckenna, Mavis
Srivastava, Arun
Abrégé
Disclosed are capsid-modified rAAV particles and expression vectors, as well as compositions and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and using novel capsid-protein-mutated particle or rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for subretinal delivery of therapeutic gene constructs to mammalian photoreceptors and retinal pigment epithelial cells, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications including the treatment of a variety of inherited retinal diseases.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Chou, Janice J.
Byrne, Barry J.
Abrégé
The present disclosure describes improved adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type la (GSD-Ia). Described are recombinant nucleic acid molecules, vectors and recombinant AAV that include a G6PC promoter/enhancer, a synthetic intron, a G6PC coding sequence (such as a wild-type or codon-optimized G6PC coding sequence), and stuffer nucleic acid sequence situated between the G6PC promoter/enhancer and the intron, as well as between the intron and the G6PC coding sequence. The recombinant AAVs disclosed herein exhibit highly efficient liver transduction and are capable of correcting metabolic abnormalities in an animal model of GSD-Ia.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Herzog, Roland W.
Daniell, Henry
Abrégé
Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life -threatening anaphylactic reactions by formation of lgE. Using murine hemophilia as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of coagulation factor expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated subjects when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after 4 to 6 exposures to intravenous coagulation factor protein.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A01H 5/00 - Angiospermes, c. à d. plantes à fleurs, caractérisées par leurs parties végétales; Angiospermes caractérisées autrement que par leur taxonomie botanique
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres lyophilisées
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Daniell, Henry
Li, Qiuhong
Raizada, Mohan K.
Abrégé
Low activity of angiotensin converting enzyme2 (ACE2) and its product, angiotensin-(1-7) [Ang-(1-7)] appear to contribute to pulmonary hypertension (PH). Long-term delivery of ACE2 or Ang-(1-7) require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastricenzymes and to facilitate absorption. Rats fed with bioencapsulated ACE2 or Ang-(1-7) exhibited improved heart function. A combination of ACE2 and Ang-(1-7) augmented the beneficial effects. Experiments indicate that this method is suitable for the treatmen or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for transplastomic technology as a novel low-cost oral ACE2 or Ang-(1-7) delivery system.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Marsic, Damien
Zolotukhin, Sergei
Agbandje-Mckenna, Mavis
Abrégé
Disclosed are compositions and methods for producing modified adeno-associated virus (AAV) cap genes and combinatorial libraries of chimeric AAV vectors and virions; selecting for virions displaying cell-specific tropisms; and, in certain embodiments, producing helper vectors containing one or more modified AAV cap genes. The synthetic combinatorial AAV capsid libraries of the invention are useful in introducing into selected target host cells one or more nucleic acid molecules. The viral vectors and genetic constructs disclosed herein are also useful in a variety of diagnostic and/or therapeutic gene-therapy regimens.